School of Medicine Funding Search Tool

Below is a curated, searchable and filterable list of funding opportunities announced by NIH in their weekly NIH guide LISTSERV. This list reflects funding opportunities pertinent to many UCI researchers. Using filters may reduce your results, so use judiciously. Opportunities are added weekly.

You can sign up for the NIH guide listserv to receive a comprehensive list of funding opportunities every Friday.

NIH Guide Listserv

Date Range

2024 Deadline 2: Jun 16, 2024

Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) (PAR-23-301)

The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.

2024 Deadline 1: Jun 16, 2024

New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) (PAR-24-161)

The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment.

2024 Deadline: Jun 18, 2024

BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) (RFA-EY-23-001)

This NOFO seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization.

2024 Deadline: Jun 19, 2024

Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) (PAR-23-177)

The National Center for Advancing Translational Sciences (NCATS) invites applications for the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) Notice of Funding Opportunity (NOFO) to foster investigator-initiated development of highly innovative technologies to address barriers, limitations, or bottlenecks in translational science – particularly for therapeutic development.

2024 Deadline 1: Jun 28, 2024

BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed) (RFA-NS-23-023)

This R34 NOFO solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - Targeted BCP R01, as described in the companion NOFO (RFA-NS-23-024).

2024 Deadline 2: Jul 02, 2024

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) (PAR-24-036)

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions.

2024 Deadline: Jul 08, 2024

Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional) (RFA-HG-23-017)

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations.

2024 Deadline: Jul 08, 2024

Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional) (RFA-HG-23-018)

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations.